Hematologic Malignancy
AL Amyloidosis
CI-CAN-00008703Explore in graph →
HematologicNon-malignant31 active trials
- NCIt
- C158963
- MeSH
- D000075363
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00008703Explore in graph →
Clinical trials
79 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04504825 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) | active not recruiting | Phase 3 | 125 | Alexion Pharmaceuticals, Inc.INDUSTRY | 19 | Jul 2, 2026 | clinicaltrials |
| NCT04512235 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) | active not recruiting | Phase 3 | 281 | Alexion Pharmaceuticals, Inc.INDUSTRY | 19 | Jun 17, 2026 |
Data updated 22 days agoSource updated Jul 2, 2026source: clinicaltrials